Pediatric drugs

Discover the landscape of Pediatric drugs in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Pediatric drugs, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran
CompanyDeals

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran

Merck KGaA (ETR: MRK) announced that it has entered into a definitive agreement to acquire Silence Therapeutics plc (NASDAQ: SLN), a UK‑headquartered global clinical‑stage biotechnology company pioneering siRNA therapies in…

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment

DrugR&D

Shanghai’s 9th People’s Hospital Launches Groundbreaking Gene Therapy Trial for Congenital Deafness

CompanyDrug

GSK’s ViiV Healthcare Expands Dovato Indication to Include Adolescents with HIV-1 Infection

CompanyDrug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

CompanyDrug

Amgen Reports Positive Results for Otezla in Pediatric Psoriasis Trial

Policy / Regulatory

China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024

CompanyDrug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

CompanyDrug

Hainan Poly Pharm Secures Tentative FDA Approval for Generic Version of UCB’s Briviact

Show More